Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi
Tools, data and results from chapter 3 of the report 'A review of country-level HIV planning and resource allocation tools and processes: the development of National Strategic Plans and their links to
‡Assuming a 100% increase in at-risk behavior. ¶Assuming $700 per person-year of PrEP; the market price of a generic version of tenofovir (Tenvir) manufactured by Cipla in India [87]. §Assuming $318 p
HIV treatment and prevention as well as other chronic disease care can require regular kidney function assessment based on a creatinine test. To assess the costs of creatinine testing in a public heal
